President and Chief Executive Officer
Jennifer Dent, President & CEO is responsible for setting the organization’s strategy, determining its programs, and working with the BVGH team to establish partnerships and deliver on program objectives. She joined BVGH in 2011 and took over leadership of the organization in 2012. She has facilitated partnerships across the private, government, and public sectors involving more than 50 countries. Jennifer leverages her international industry experience to tackle tough global health challenges with market-driven approaches focusing on sustainability, scalability, and most importantly, priorities and needs as determined by each African or low- and middle-income country partner. Prior to joining BVGH, Jennifer worked for Hoffmann-La Roche as an Alliance Director in South San Francisco at the Genentech site. She has 20+ years of broad-based pharmaceutical and biotechnology experience, including negotiation and structuring of deals, and management of global discovery and commercial alliances. Jennifer began her career as a sales representative in Canada working in a variety of positions for Parke Davis/Pfizer and Genentech. Following the acquisition of Genentech Canada by Roche, Jennifer held a number of senior management positions in marketing, life cycle management, global product strategy, business development, and alliance management at Roche and Genentech in Canada, Switzerland, New Jersey, and South San Francisco. Jennifer co-founded Sound Biotechnology, and prior to that, served as Vice President, Business Development, Marketing, and Sales at CombiMatrix Corporation in Washington State.
Jennifer received her MBA from the Richard Ivey School of Business, Western University and her BSc from Western University in Canada. In her spare time, Jennifer can be found in her garden or spending time with family and friends.